Cryptic activation of an Irf8 enhancer governs cDC1 fate specification-Reference-Cited by-同舟云学术

Cryptic activation of an Irf8 enhancer governs cDC1 fate specification

Published:2019-08-12 Issue:9 Volume:20 Page:1161-1173
ISSN:1529-2908
Container-title:Nature Immunology
language:en
Short-container-title:Nat Immunol

Author:

Durai Vivek,Bagadia Prachi,Granja Jeffrey M.,Satpathy Ansuman T.^ORCID,Kulkarni Devesha H.,Davidson Jesse T.^ORCID,Wu Renee,Patel Swapneel J.^ORCID,Iwata Arifumi,Liu Tian-Tian,Huang Xiao,Briseño Carlos G.,Grajales-Reyes Gary E.,Wöhner Miriam,Tagoh Hiromi,Kee Barbara L.^ORCID,Newberry Rodney D.^ORCID,Busslinger Meinrad,Chang Howard Y.^ORCID,Murphy Theresa L.,Murphy Kenneth M.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

http://www.nature.com/articles/s41590-019-0450-x.pdf

Reference57 articles.

1. Graf, T. & Enver, T. Forcing cells to change lineages. Nature 462, 587–594 (2009).

2. Orkin, S. H. & Zon, L. I. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 132, 631–644 (2008).

3. Miyamoto, T. et al. Myeloid or lymphoid promiscuity as a critical step in hematopoietic lineage commitment. Dev. Cell 3, 137–147 (2002).

4. Hoppe, P. S. et al. Early myeloid lineage choice is not initiated by random PU.1 to GATA1 protein ratios. Nature 535, 299–302 (2016).

5. Long, H. K., Prescott, S. L. & Wysocka, J. Ever-changing landscapes: transcriptional enhancers in development and evolution. Cell 167, 1170–1187 (2016).

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy;Nature;2024-07-24

2. Progenitors of distinct lineages shape the diversity of mature type 2 conventional dendritic cells;Immunity;2024-07

3. Hypoxia inhibits the iMo/cDC2/CD8+ TRMs immune axis in the tumor microenvironment of human esophageal cancer;Journal for ImmunoTherapy of Cancer;2024-07

4. Ontogeny and Function of Plasmacytoid Dendritic Cells;Annual Review of Immunology;2024-06-28

5. PIKfyve, expressed by CD11c-positive cells, controls tumor immunity;Nature Communications;2024-06-28